- Home
- CLOV vs ATAI Comparison
CLOV vs ATAI Comparison
Compare CLOV & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLOV | ATAI |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CLOV | ATAI |
|---|---|---|
| Price | $2.69 | $4.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $2.90 | ★ $15.88 |
| AVG Volume (30 Days) | 5.1M | ★ 6.7M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.03 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,924,308,000.00 | $4,089,000.00 |
| Revenue This Year | $52.59 | N/A |
| Revenue Next Year | $15.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 40.34 | ★ 1227.60 |
| 52 Week Low | $1.58 | $1.29 |
| 52 Week High | $3.92 | $6.73 |
Technical Indicators
Market Signals| Indicator | CLOV | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 71.17 | 52.22 |
| Support Level | $2.51 | $4.05 |
| Resistance Level | $2.81 | $4.24 |
| Average True Range (ATR) | 0.13 | 0.33 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 86.79 | 16.29 |
Price Performance
Historical ComparisonAbout CLOV Clover Health Investments Corp.
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.